Navigation Links
MIT researcher addresses biomedical engineering challenges
Date:2/15/2008

the development of novel ways to introduce DNA strands into human cells, a necessary step in gene therapy to correct genetic abnormalities or predispositions to disease.

Traditionally, such DNA insertions have been carried out using viruses that have a natural ability to penetrate the cell and insert segments of DNA into the nucleus. But these viruses can sometimes have dangerous side effects, and have been responsible for deaths in some early gene-therapy trials.

Were working on polymers that could deliver DNA as efficiently as viruses, that could put a DNA strand wherever you want, without the safety problems of viruses, Langer says. In addition, they could be cheaper and easier to manufacture.

So far, the problem has been that such synthetic vectors have been far less efficient in carrying out the delivery. But in early tests conducted by Jordan Green and Dan Anderson in Langers lab, some polymers have been as effective at delivering the DNA strands to their target as the viruses, but with 100 times less toxicity.

Such new polymers, Langer says, might eventually lead to new treatments for some kinds of cancer. And they may also enable the delivery of small interfering RNA segments (siRNAs), whose discovery led to a Nobel Prize in 2006. These may be used to combat a variety of diseases.

Anderson, Langer and graduate student Michael Goldberg have also been working on the design of chemicals similar to lipids in the body, called lipidoids that could be used to deliver drugs including siRNA to specific tissues in the body and release them in a controlled way. Already more than 50 promising compounds have been found and are undergoing tests. That work is going quite well, Langer says.

Tissue engineering is another important area of ongoing research, Langer says. One key project is growing replacements for damaged tissues such as the neurons damaged by spinal cord injuries that lead to paralysis. Using a neuronal sc
'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers
2. A researcher of UPV/EHU has designed nanomagnets for industry
3. Stanford researchers hear the sound of quantum drums
4. Researchers at Leeds mine the Terahertz gap
5. Researchers create gold aluminum, black platinum, blue silver
6. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
7. Researchers Pinpoint Best Treatment to Reduce Deadly USA300, MRSA Staph Infections
8. Researchers develop darkest manmade material
9. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
10. Researchers use magnetism to target cells to animal arteries
11. Ames Laboratory researchers solve fuel-cell membrane structure conundrum
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2